Shionogi's Xocova has just won FDA approval as the first oral antiviral medication designed to stop COVID-19 before it starts — a five-day course taken by people who've been exposed to the virus but haven't yet gotten sick. The approval marks a meaningful shift in how we might prevent COVID-19 from taking hold in high-risk situations, from family homes to nursing facilities.
The decision rests on solid clinical evidence. The Phase III SCORPIO-PEP trial followed 2,387 people who had been exposed to someone with symptomatic COVID-19 in their household but tested negative and showed no symptoms themselves when they enrolled. Those given Xocova saw their risk of developing symptomatic COVID-19 drop by 67 percent through day 10 compared with placebo — a substantial protective effect. The medication itself is straightforward: three tablets on day one (375 mg total) followed by one tablet daily for four more days (125 mg each).
Safety data aligned with what researchers hoped to see. Adverse events occurred at similar rates in both the Xocova group and placebo group — 15.1 percent versus 15.5 percent — suggesting the drug was well tolerated. The most frequent side effects were headache, diarrhea, and cough, each occurring in at least 1 percent of people who took the medication, and generally at slightly higher rates than in the placebo arm. Nothing unexpected emerged.
What makes this approval particularly significant is the opening it creates for prevention strategies beyond vaccination and basic hygiene. Frederick Hayden, an infectious disease specialist at the University of Virginia School of Medicine, captured this potential in his comments: "The PEP strategy has the potential to benefit anyone who does not want to get COVID-19. It could be useful not only in household settings but also in other exposure circumstances, such as outbreaks in nursing homes, chronic or acute care facilities, and following travel-related exposures."
That breadth matters. A parent exposed to their child's infection, an immunocompromised resident in a long-term care facility, a healthcare worker after a needlestick injury — all now have a concrete option to reduce their odds of falling ill. The five-day regimen is brief enough to fit into people's lives without becoming burdensome, and the fact that it's an oral medication (rather than an injection or infusion) lowers barriers to access and uptake.
COVID-19 continues to circulate globally and still claims lives. While vaccination remains the cornerstone of protection, new variants keep emerging, and some people remain vulnerable despite vaccination. A preventive tool that works across different exposure scenarios, and that comes with a manageable side effect profile, addresses a genuine gap in our pandemic toolkit. Xocova won't replace vaccines or other prevention measures, but it enlarges the options available to clinicians and patients trying to stay healthy in an unpredictable landscape.
The approval underscores how postexposure prevention — once most familiar from HIV and rabies protocols — is becoming a more visible part of COVID-19 strategy. As the virus settles into endemicity, having multiple proven approaches to keep people well gives reason for cautious optimism about managing both acute outbreaks and the ongoing burden of disease.